Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Trial ID or NCT#
NCT00070291
Status
NOT RECRUITING
Purpose
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.
Official Title
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- * Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination.* At least one objective measurable or evaluable disease parameter.* Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy.* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.* Adequate renal function as indicated by creatinine \<= 1.5 the upper limit of normal (ULN).* Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<= 2x the upper limit of normal.* Total bilirubin \<= 2x the upper limit of normal.* Age 18 or older.
Exclusion Criteria:
- * Prior cyclosporine or Tacrolimus (FK506).* Prior allogeneic transplant.* Evidence of active infection.* Congestive heart failure, kidney failure, liver failure, or other severe co-morbidities.* Evidence of active neurological impairment.* Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil).* History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin).* pregnant or breastfeeding women.* Human immunodeficiency virus (HIV) positive.
Investigator(s)
Harlan Pinto
Medical oncologist,
Head and neck specialist
Associate Professor of Medicine (Oncology), Emeritus
Sandra Horning
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
6504987061
View on